BioTuesdays

Tag - BTIG

Precision Biosciences
Markets

BTIG starts Precision BioSciences at buy; PT $22

BTIG initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $22 price target, representing upside of approximately 100% from a closing price of $10.98 on Aug. 8. “While Precision only recently...

August 9, 2019
ViewRay Logo
Markets

BTIG cuts ViewRay PT to $6 from $10

BTIG lowered its price target for ViewRay (NASDAQ:VRAY) to $6 from $10 after the company reported second quarter results. The stock closed at $6.74 on Aug. 8 but was down to $3.35 in after hours trading. ViewRay, which...

August 9, 2019
Markets

BTIG starts Cellectis at buy; PT $37

BTIG launched coverage of Cellectis SA (NASDAQ:CLLS; Euronext Growth:ALCLS) with a “buy” rating and $37 price target. The stock closed at $13.86 on Aug. 8. “Despite the initial positive reaction from investors to...

August 9, 2019
TransEnterix Logo
Markets

BTIG halves TransEnterix PT to $1.50 from $3

BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...

August 8, 2019
ConforMIS
Developments

BTIG cuts Conformis to neutral

BTIG downgraded Conformis (NASDAQ:CFMS) to “neutral” from “buy” following release of the company’s second quarter results. BTIG does not publish price targets on neutral-rated stocks. Conformis, which closed at $2.76 on...

August 1, 2019
Homology Logo
Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018
NeoGenomics
Markets

BTIG ups NeoGenomics to buy; PT $11

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral” with a price target of $11, saying that with a cleaner slate, it expects the shares to outperform. The stock closed at $8.49 on April 13. Analyst Dr. Sean...

April 16, 2018
Obalon Therapeutics
Markets

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

March 6, 2018
Cerus
Markets

BTIG ups Cerus price target to $10

BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a...

April 22, 2016